Cargando…

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Detalles Bibliográficos
Autores principales:	Wenzel, Mike, Nocera, Luigi, Collà Ruvolo, Claudia, Würnschimmel, Christoph, Tian, Zhe, Shariat, Shahrokh F., Saad, Fred, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Briganti, Alberto, Mandel, Philipp, Montorsi, Francesco, Chun, Felix K. H., Karakiewicz, Pierre I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638077/ https://www.ncbi.nlm.nih.gov/pubmed/36899091 http://dx.doi.org/10.1038/s41391-023-00656-4

Ejemplares similares

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2021)

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
por: Würnschimmel, Christoph, et al.
Publicado: (2021)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma
por: Wenzel, Mike, et al.
Publicado: (2021)

Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables
por: Würnschimmel, Christoph, et al.
Publicado: (2022)

Incidence rates and contemporary trends in primary urethral cancer
por: Wenzel, Mike, et al.
Publicado: (2021)

Bladder cancer stage and mortality: urban vs. rural residency
por: Deuker, Marina, et al.
Publicado: (2020)

The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
por: Wenzel, Mike, et al.
Publicado: (2021)

The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy
por: Wenzel, Mike, et al.
Publicado: (2022)

Epidemiology of Unconventional Histological Subtypes of Urethral Cancer
por: Wenzel, Mike, et al.
Publicado: (2023)

Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerations
por: Nocera, Luigi, et al.
Publicado: (2022)

Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy
por: Wenzel, Mike, et al.
Publicado: (2021)

Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy
por: Collà Ruvolo , Claudia, et al.
Publicado: (2021)

Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
por: Chowdhury, Simon, et al.
Publicado: (2021)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Hoeh, Benedikt, et al.
Publicado: (2021)

Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Comparison Between Urothelial and Non-Urothelial Urethral Cancer
por: Wenzel, Mike, et al.
Publicado: (2021)

Differences in long-term continence rates between prostate cancer patients with extraprostatic vs. organ-confined disease undergoing robotic-assisted radical prostatectomy: An observational studys
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Differences between rural and urban prostate cancer patients
por: Stolzenbach, Lara Franziska, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
por: Lam, Wing, et al.
Publicado: (2023)

Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
por: Gupta, Siddharth, et al.
Publicado: (2020)

Radiation therapy after radical prostatectomy is associated with higher other-cause mortality
por: Würnschimmel, Christoph, et al.
Publicado: (2022)

MRI as a screening tool for prostate cancer: current evidence and future challenges
por: Würnschimmel, Christoph, et al.
Publicado: (2022)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
por: Hussain, Arif, et al.
Publicado: (2022)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients
por: Preisser, Felix, et al.
Publicado: (2018)

Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2020)

Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients
por: Hoeh, Benedikt, et al.
Publicado: (2021)

Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
por: Mandel, Philipp, et al.
Publicado: (2021)

Comparison of peri- and intraoperative outcomes of open vs robotic-assisted partial nephrectomy for renal cell carcinoma: a propensity-matched analysis
por: Hoeh, Benedikt, et al.
Publicado: (2023)

Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nns5kb2jcsa9pedq6k6f2vftek